Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;26(6):1069-1080.
doi: 10.1093/annonc/mdv019. Epub 2015 Jan 20.

Genetic lesions in diffuse large B-cell lymphomas

M Testoni  1 , E Zucca  2 , K H Young  3 , F Bertoni  4
Affiliations
Review

Genetic lesions in diffuse large B-cell lymphomas

M Testoni et al. Ann Oncol. 2015 Jun.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, accounting for 35%-40% of all cases. The combination of the anti-CD20 monoclonal antibody rituximab with anthracycline-based combination chemotherapy (R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) lead to complete remission in most and can cure more than half of patients with DLBCL. The diversity in clinical presentation, as well as the pathologic and biologic heterogeneity, suggests that DLBCL comprises several disease entities that might ultimately benefit from different therapeutic approaches. In this review, we summarize the current literature focusing on the genetic lesions identified in DLBCL.

Keywords: BCL2; BCl6; MYC; MYD88; NF-κB.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Frequency of DNA gains and losses in diffuse large B-cell lymphoma (DLBCL) (A) and examples of genomic profiles from two cases of germinal center B-cell-like (GCB) DLBCL (B and C) and two cases of activated B-cell-like (ABC) DLBCL (D and E). A: Frequency of DNA gains (upper plot, red) and losses (lower plot, blue) is shown in 172 cases of DLBCL analyzed using the Affymetrix Human mapping 250k NspI array. B–E: Genomic profiles were obtained using the Affymetrix Genome-Wide Human SNP Array Version 6.0. Black indicates raw copy number values and red indicates smoothed copy number values. The x-axis shows genomic mapping and the y-axis shows log2 copy number values.
Figure 2.
Figure 2.
The 50 most mutated genes in diffuse large B-cell lymphoma as registered at the Catalogue of Somatic Mutations in Cancer database [35]. Data accessed on 4 August 2014.
Figure 3.
Figure 3.
Schematic diagram showing the BCR, NF-κB, TLR and JAK/STAT signaling cascade, emphasizing the proteins affected by activating or inactivating genetic lesions and the classes of therapeutic targeted agents. Orange squares: proteins activated by genetic lesions. Blue squares: proteins inactivated by genetic lesions. Green squares: classes of therapeutic targeted agents.
See this image and copyright information in PMC

References

    1. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol 2007; 18(Suppl 1): i3–i8. - PubMed
    1. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110: 29–36. - PubMed
    1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008; 439.
    1. Martinez-Climent JA, Alizadeh AA, Segraves R, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 2003; 101: 3109–3117. - PubMed
    1. de Jong D, de Boer JP. Predicting transformation in follicular lymphoma. Leuk Lymphoma 2009; 50: 1406–1411. - PubMed

Publication types

MeSH terms

Substances